Navigation Links
Certifications, Presentation of Study Results and Earnings Releases - Research Report on Agilent, Mindray, Bard, Tornier, and Life Technologies
Date:11/11/2013

2 Co-Primary Investigator, presented data related to the study design, demographics, and six-month follow-up results from the patients randomized in the LEVANT 2 Lutonix Drug-Coated Balloon (DCB) trial, at the Transcatheter Cardiovascular Therapies (TCT) conference in San Francisco, California. The Company informed that the follow-up results from randomized patients, treated with the Lutonix DCB demonstrated safety comparable to uncoated balloons (94.0% vs 94.1%) and superior primary patency (92.3% vs 82.7%, p=0.003) by Kaplan-Meier time-to-event analysis. According to Bard, interested parties may access the presentation slides at the Company website, which will be available for a limited time period. The Full Research Report on C.R. Bard, Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/141e_BCR]

--

Tornier N.V. Research Report

On November 5, 2013, Tornier N.V. (Tornier) released its Q3 FY 2013 financial results (period ended September 29, 2013) with revenues of $66.7 million, up 15.1% YoY. Q3 FY 2013 revenue of the Company's extremities product categories totaled $56.9 million, compared to $48.7 million in Q3 FY 2012. Tornier also reported that non-GAAP gross margins improved to 74.2% in Q3 FY 2013 from 73.4% in Q3 FY 2012. Dave Mowry, President and CEO of Tornier, said, "We delivered adjusted EBITDA within our guidance range despite the lower than expected revenue. This was driven by an improvement in non-GAAP gross margin and prudent management of operating expenses. We believe we have the infrastructure in place to support our double-digit constant currency revenue growth and enhanced operating leverage expectations." Tornier stated that for Q4 FY 2013 it expects constant currency
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. HeartWare Presentation At The Canaccord Genuity Medical Technology & Diagnostics Forum To Be Webcast
2. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
3. Hologic to Host Investor Presentation at RSNA 2013
4. Thoratec Announces Presentations At Investor Conferences For November 2013
5. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
6. Vital Access Reports Live VWING Clinical Cases and SAVE Study Clinical Data Presentation at CiDA Conference
7. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
8. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
9. Healthcare Sector Announced Clinical Data Presentation, Upcoming Financial Release Schedules and Updates on New Drug Applications - Research Report on Alexion, Pacira, pSivida, Momenta and Impax
10. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
11. Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- Research and Markets has announced ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study ... devices. The report provides a basic ... and industry chain structure. The laparoscopic devices market ...
(Date:9/16/2014)... 16, 2014   Vestagen Technical Textiles, Inc. ... at hospitals. The myComfort™ line of patient apparel is ... that is fluid repellant, breathable and in studies done ... of bacteria on the fabric i . ... the chain of transmission. We want myComfort to be ...
(Date:9/16/2014)... BRIDGEWATER, N.J. , Sept. 16, 2014 /PRNewswire/ ... pharmaceutical company focused on developing and commercializing therapeutic ... renal and infectious diseases, announces the amendment and ... and E preferred stock and related warrants, as ... 2014 common stock and warrant financing, to remove ...
Breaking Medicine Technology:Global Laparoscopy Devices Industry Report 2014 2New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... Pa., Feb. 16, 2011 AirPal, a medical device ... of allowance from the U.S. Patent Office for its ... for situations such as difficult airway management, laryngoscopies, diagnostic ... founded in 1982, now holds more than a dozen ...
... YORK, Feb. 16, 2011 Get content from ... The European Parliament is expected ... prevent falsified medicines from entering the legal distribution ... packages have reached patients in the last years. ...
Cached Medicine Technology:AirPal Receives Patent for Inflatable Patient Positioning Systems 2
(Date:9/16/2014)... Top10BestSEOHosting.com has recently compared many ... companies for the webmasters that want to buy ... , The senior spokesman for Top10BestSEOHosting.com says, “We ... HostMonster are the excellent hosting companies for worldwide ... wide range of advanced features while still maintaining ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 Dog Food ... dog owners the true poisonous ingredients in most commercial dog ... recipes has caught the attention of Shane Michaels, prompting an ... just as much of a family member as any other ... dog dies earlier than it should due to poor diet” ...
(Date:9/16/2014)... in the UK report a poorer experience of care ... focus on their care, suggests a new study published ... of Obstetrics and Gynaecology ( BJOG ). , ... been demonstrated in many areas and have provided the ... the observed inequalities. , The Oxford University study, funded ...
(Date:9/16/2014)... St. Petersburg, FL (PRWEB) September 17, 2014 ... face with beautiful skin on the neck. , "The ... for this delicate skin," says Kathy Heshelow, founder of Sublime ... such as coconut oil, aloe, MSM and arnica." , A ... relax lines and wrinkles. , The rich anti-aging cream comes ...
(Date:9/16/2014)... Park City, UT (PRWEB) September 16, 2014 ... Health Benefits Solution, published new information on transitioning ... to Zane Benefits, with the Affordable Care Act ... sized businesses will be steering some or all ... comes as no surprise. With guaranteed issue plans, ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: Arvixe Is One Of The Best SEO Hosting Suppliers 2Health News:Dog Food Secrets: Review Exposes Andrew Lewis’ Guide to Happier, Healthier Dogs with Homemade Dog Food 2Health News:A greater focus on socially disadvantaged women is needed to improve maternity care in England 2Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2
... C with the standard therapy of pegylated-interferon and ribavirin would ... of Hepatology, a journal published by John Wiley ... Study of Liver Diseases (AASLD). The article is also available ... prisons incarcerate more than 2 million inmates each year, and ...
... to Be Served Beginning in ... ... been awarded the five-year Active Duty Dental Program (ADDP),contract by the United ... be awarded to the Harrisburg, PA-based,national dental insurer. The contract, which is ...
... Some Payers Scaling Back Chronic Disease,Initiatives, WASHINGTON, ... to reports that many Americans are forgoing basic,medical ... renewed vigilance,in the fight against chronic disease and ... of belt-tightening make sense in tough economic times,--dining ...
... & Grossman, LLC,announces that a class action lawsuit has ... District of Colorado against The Spectranetics,Corporation. ("Spectranetics" or the ... of purchasers of Spectranetics who purchased common,stock between April ... According to the complaint, the true facts, which ...
... channel count 12-bit ADC with Samplify,s, Prism(TM) data ... in ... SANTA CLARA, Calif., Oct. 20 Samplify ... family of true,16-channel, 12-bit, 65 Msample/sec analog-to-digital converter ...
... 20 Concentric Medical,Inc., the global leader in ... announced the launch of the Merci(R) Distal Access,Catheter, ... and enhanced support during minimally invasive procedures in ... using the Merci Retrieval System(TM),to remove thrombus in ...
Cached Medicine News:Health News:Hepatitis C treatment is cost-effective for the US prison population 2Health News:National Dental Insurer United Concordia to Receive $660 Million Contract From U.S. Department of Defense 2Health News:Nation's Economic Downturn Threatens Continuity of Care for Chronic Conditions 2Health News:Bronstein, Gewirtz & Grossman, LLC Announces that a Class Action has been Filed Against The Spectranetics Corporation 2Health News:Samplify Systems Announces Availability of World's First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression 2Health News:Samplify Systems Announces Availability of World's First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression 3Health News:Samplify Systems Announces Availability of World's First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression 4Health News:Samplify Systems Announces Availability of World's First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression 5
Agarose IEF is suitable for isoelectric focusing of large molecules and is the gel of choice for many IEF applications and immunochemical detection methods....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... White solid. Highly purified non-ionic fraction of ... at very low concentrations. Can be mounted ... dried, films are elastic and durable and ... with either protein or lipoprotein dyes. ...
Medicine Products: